Progress of fragility fracture in patients with acquired immune deficiency syndrome

doi:10.3877/cma.j.issn.1674-1358.2018.03.004

Abstract

Abstract:

The incidence of acquired immune deficiency syndrome (AIDS) in general population increased gradually, but the mortality of patients with AIDS decreased gradually with the application of highly effective antiretroviral therapy, and the incidence of fragility fracture in patients with AIDS is significantly higher than that of normal population. This paper introduces the occurrence of fragility fracture of AIDS, the effect of human immunodeficiency virus (HIV) and highly active antiretroviral therapy (HAART) on osteoblasts and osteoclasts OPG/RANK/RANKL system. Prevention and treatment of drugs to AIDS patients with fragility fracture was also introduced.

Key words: Acquired immune deficiency syndrome, Osteoporosis, Fragility fracture, Mechanism, Drug

Shuai Wang, Rugang Zhao, Qiang Zhang. Progress of fragility fracture in patients with acquired immune deficiency syndrome[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(03): 221-224.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2018.03.004

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2018/V12/I03/221

References 32

[1]	戴色莺, 沈张伟, 范引光, 等. 我国艾滋病预防控制中流行病学研究进展[J]. 中华疾病控制杂志,2015,19(12):1282-1285.
[2]	佚名. 2016年5月全国艾滋病性病疫情及主要防治工作进展[J]. 中国艾滋病性病,2016(7):487.
[3]	王辉, 周伯平. AIDS抗病毒药物的不良反应[J]. 传染病信息,2014(6):369-372.
[4]	Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review[J]. AIDS,2006,20(17):2165-2174.
[5]	Hoy J, Young B. Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?[J]. Curr Opin HIV AIDS,2016,11(3):301.
[6]	Mccomsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers[J]. Clini Infect Dis,2010,51(8):937-946.
[7]	Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system[J]. J Clin Endocrinol Metab,2008,93(9):3499-3504.
[8]	Shiau S, Broun EC, Arpadi SM, et al. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis[J]. AIDS,2013,27(12):1949-1957.
[9]	Torti C, Mazziotti G, Soldini PA, et al. High prevalence of radiological vertebral fractures in HIV-infected males[J]. Endocrine,2012,41(3):512-517.
[10]	王萍萍, 柯耀华, 张浩, 等. 绝经后妇女740例脆性骨折部位与骨密度关系的分析[J]. 中国科医学,2010,13(4):372-373.
[11]	陈瑾瑜, 游利, 潘凌, 等. 老年患者脆性骨折1072例分析[J]. 世界临床药物,2016(6):385-389.
[12]	Haskelberg H, Carr A, Emery S. Bone turnover markers in HIV disease[J]. AIDS Rev,2011,13(4):240-250.
[13]	Natsag J, Kendall M, Sellmeyer D, et al. Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappa B ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density[J]. HIV Med,2016,17(3):196-205.
[14]	张久聪, 郑晓凤, 汪泳, 等. 获得性免疫缺陷综合征抗病毒治疗药物研究进展[J]. 生物技术通讯,2016,27(5):732-737.
[15]	Mary-Krause M, Viard J, Ename-Mkoumazok B, et al. Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy[J]. J Clin Densitom,2012,15(4): 422-433.
[16]	Grant PM, Kitch D, Mccomsey GA, et al. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults[J]. HIV Clin Trials,2015,16(2):66-71.
[17]	Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study[J]. J Infect Dis,2009,200(11): 1746-1754.
[18]	Lima ALLM, Godoy AL, Gobbi RG, et al. Orthopedic complictions in HIV patients [J]. Rev Bras Ortop,2009,44(3):186-190.
[19]	Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans[J]. PLoS One,2011,6(2):e17217.
[20]	Bedimo R, Maalouf N M, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents[J]. AIDS,2012,26(7):825-831.
[21]	Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials[J]. Lancet,2015,385(9987):2606-2615.
[22]	Moran CA, Weitzmann MN, Ofotokun I. Bone Loss in HIV Infection[J]. Curr Treat Options Infect Dis,2017,9(1):52-67.
[23]	Grant PM, Kitch D, Mccomsey GA, et al. Low baseline CD4⁺ count is associated with greater bone mineral density loss after antiretroviral therapy initiation[J]. Cli Infect Dis,2013,57(10):1483-1488.
[24]	Hansen AE, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection[J]. AIDS,2012,26(3):285-293.
[25]	Bregigeon S, Galinier A, Zaegelfaucher O, et al. Frailty in HIV infected people: a new risk factor for bone mineral density loss[J]. Aids,2017,31(11):1573-1577.
[26]	Shahar E, Segal E, Rozen GS, et al. Vitamin D status in young HIV infected women of various ethnic origins: Incidence of vitamin D deficiency and possible impact on bone density[J]. Clin Nutr,2013,32(1):83-87.
[27]	Albright P, Du P, Haas RE, et al. Evidence-based screening for low bone mineral density in HIV-infected men[J]. J Assoc Nurses AIDS Care,2014,25(6):532-540.
[28]	Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006[J]. Clin Infect Dis,2011,52(8):1061-1068.
[29]	Mayer KH, Amorosa V, Tebas P. Bone disease and HIV infection[J]. Clin Infect Dis,2006,43(1):111-112.
[30]	Pinzone MR, Moreno S, Cacopardo B, et al. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis[J]. AIDS Rev,2014,16(4):213-222.
[31]	Cummings SR, San MJ, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J]. N Engl J Med,2009,361(8):756-765.
[32]	Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the multiple outcomes of raloxifene evaluation (MORE) study[J]. J Bone Miner Res,2004,19(5):764-772.

Please choose a citation manager

Content to export